127 related articles for article (PubMed ID: 3491727)
1. Natural immunity against ovarian tumors.
Lotzová E; Savary CA; Freedman R; Bowen JM
Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):269-75. PubMed ID: 3491727
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract.
Lotzová E; Savary CA; Freedman RS; Bowen JM
Cancer Immunol Immunother; 1984; 17(2):124-9. PubMed ID: 6205745
[TBL] [Abstract][Full Text] [Related]
3. Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors.
Mantovani A; Allavena P; Sessa C; Bolis G; Mangioni C
Int J Cancer; 1980 May; 25(5):573-82. PubMed ID: 6154662
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
[TBL] [Abstract][Full Text] [Related]
5. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells.
Robinson BW; Morstyn G
Cell Immunol; 1987 May; 106(2):215-22. PubMed ID: 3494538
[TBL] [Abstract][Full Text] [Related]
6. Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer.
Furukawa K; Lotzová E; Freedman RS; Bowen JB; Edwards CL; Wharton JT
Cancer Immunol Immunother; 1989; 30(2):126-32. PubMed ID: 2598179
[TBL] [Abstract][Full Text] [Related]
7. Recombinant IL-2-activated NK cells mediate LAK activity against ovarian cancer.
Lotzová E; Savary CA; Freedman RS; Edwards CL; Wharton JT
Int J Cancer; 1988 Aug; 42(2):225-31. PubMed ID: 3261280
[TBL] [Abstract][Full Text] [Related]
8. Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinoma.
Lentz SS; Kovach JS; McKean DJ; Wieand HS; Podratz KC
Gynecol Oncol; 1990 Aug; 38(2):191-6. PubMed ID: 2387535
[TBL] [Abstract][Full Text] [Related]
9. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
12. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.
Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Ljunggren HG; Kiessling R; Malmberg KJ
J Immunol; 2009 Oct; 183(8):4921-30. PubMed ID: 19801517
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
14. Social support, psychological distress, and natural killer cell activity in ovarian cancer.
Lutgendorf SK; Sood AK; Anderson B; McGinn S; Maiseri H; Dao M; Sorosky JI; De Geest K; Ritchie J; Lubaroff DM
J Clin Oncol; 2005 Oct; 23(28):7105-13. PubMed ID: 16192594
[TBL] [Abstract][Full Text] [Related]
15. Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells.
Colotta F; Rambaldi A; Colombo N; Tabacchi L; Introna M; Mantovani A
Br J Cancer; 1983 Oct; 48(4):515-25. PubMed ID: 6626452
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell impairment in ovarian clear cell carcinoma.
Patrizi O; Rampinelli F; Coltrini D; Pesce S; Carlomagno S; Sivori S; Pascale A; Marcenaro E; Parolini S; Tabellini G
J Leukoc Biol; 2020 Oct; 108(4):1425-1434. PubMed ID: 32794325
[TBL] [Abstract][Full Text] [Related]
17. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia.
Alves PCM; De Angelo Andrade LAL; Petta CA; Lorand-Metze I; Derchain SF; Guimarães F
Scand J Immunol; 2011 Sep; 74(3):244-252. PubMed ID: 21595734
[TBL] [Abstract][Full Text] [Related]
19. Human natural killing against ovarian carcinoma.
Shau H; Koren HS; Dawson JR
Br J Cancer; 1983 May; 47(5):687-95. PubMed ID: 6573908
[TBL] [Abstract][Full Text] [Related]
20. Expanded CD56
Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
